Baker Bros. Advisors
Latest statistics and disclosures from Baker Bros. Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INCY, BGNE, ACAD, MDGL, RYTM, and represent 66.61% of Baker Bros. Advisors's stock portfolio.
- Added to shares of these 10 stocks: BCYC (+$79M), RVMD (+$77M), EWTX (+$50M), DNLI (+$23M), CELC (+$22M), ABCL (+$21M), STOK (+$18M), FATE (+$13M), NMRA (+$8.7M), AKRO (+$8.7M).
- Started 13 new stock positions in VTVT, ACRV, ELVN, PRAX, NMRA, ALPN, FDMT, SAGE, MURA, FATE. NAMS, DYN, GBIO.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$242M), Invitae Corporation (-$131M), IMCR (-$65M), Gracell Biotechnologies (-$21M), DAWN (-$15M), SPRY (-$11M), CATX (-$8.9M), Invitae Corp (-$6.3M), Praxis Precision Medicines I, ROIV.
- Sold out of its positions in AADI, BCEL, DAWN, Gracell Biotechnologies, NVTAQ, Invitae Corporation, Invitae Corp, Mirati Therapeutics, Praxis Precision Medicines I, SPRY.
- Baker Bros. Advisors was a net seller of stock by $-129M.
- Baker Bros. Advisors has $8.0B in assets under management (AUM), dropping by -9.29%.
- Central Index Key (CIK): 0001263508
Tip: Access up to 7 years of quarterly data
Positions held by Baker Bros. Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 87 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Incyte Corporation (INCY) | 25.9 | $2.1B | 36M | 56.97 |
|
|
| BeiGene Sponsored Adr (BGNE) | 20.7 | $1.7B | 11M | 156.39 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 9.9 | $793M | 43M | 18.49 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 6.6 | $526M | 2.0M | 267.04 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 3.5 | $277M | 6.4M | 43.33 |
|
|
| Revolution Medicines (RVMD) | 3.1 | $243M | +46% | 7.5M | 32.23 |
|
| Kymera Therapeutics (KYMR) | 3.0 | $241M | 6.0M | 40.20 |
|
|
| Abcellera Biologics (ABCL) | 1.6 | $125M | +20% | 28M | 4.53 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 1.5 | $123M | +176% | 4.9M | 24.90 |
|
| Edgewise Therapeutics (EWTX) | 1.3 | $107M | +87% | 5.8M | 18.24 |
|
| Immunocore Holdings Ads (IMCR) | 1.2 | $99M | -39% | 1.5M | 65.00 |
|
| Kodiak Sciences (KOD) | 1.1 | $91M | 17M | 5.26 |
|
|
| Roivant Sciences SHS (ROIV) | 1.0 | $78M | -2% | 7.4M | 10.54 |
|
| Replimune Group (REPL) | 1.0 | $78M | 9.5M | 8.17 |
|
|
| Denali Therapeutics (DNLI) | 1.0 | $77M | +43% | 3.7M | 20.52 |
|
| Entrada Therapeutics (TRDA) | 0.9 | $69M | 4.9M | 14.17 |
|
|
| Akero Therapeutics (AKRO) | 0.9 | $69M | +14% | 2.7M | 25.26 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.9 | $69M | 1.5M | 46.69 |
|
|
| Immatics SHS (IMTX) | 0.8 | $68M | +10% | 6.4M | 10.51 |
|
| Cerevel Therapeutics Hldng I (CERE) | 0.8 | $68M | 1.6M | 42.27 |
|
|
| argenx SE Sponsored Adr (ARGX) | 0.7 | $60M | 151k | 393.72 |
|
|
| Nurix Therapeutics (NRIX) | 0.7 | $57M | 3.9M | 14.70 |
|
|
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 0.7 | $55M | 2.8M | 19.73 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.6 | $51M | 10M | 5.08 |
|
|
| Aerovate Therapeutics (AVTE) | 0.6 | $50M | 1.7M | 29.57 |
|
|
| Sera Prognostics Class A Com (SERA) | 0.6 | $50M | 5.4M | 9.10 |
|
|
| Prelude Therapeutics (PRLD) | 0.6 | $48M | 10M | 4.74 |
|
|
| Ideaya Biosciences (IDYA) | 0.6 | $47M | 1.1M | 43.88 |
|
|
| Stoke Therapeutics (STOK) | 0.6 | $46M | +65% | 3.4M | 13.50 |
|
| Xenon Pharmaceuticals (XENE) | 0.5 | $43M | 994k | 43.05 |
|
|
| Igm Biosciences (IGMS) | 0.5 | $40M | +10% | 4.1M | 9.65 |
|
| Cerus Corporation (CERS) | 0.5 | $37M | 20M | 1.89 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.4 | $35M | 4.9M | 7.05 |
|
|
| Celcuity (CELC) | 0.4 | $34M | +189% | 1.6M | 21.60 |
|
| Biomea Fusion (BMEA) | 0.4 | $32M | 2.1M | 14.95 |
|
|
| Krystal Biotech (KRYS) | 0.4 | $30M | 170k | 177.93 |
|
|
| Sana Biotechnology (SANA) | 0.3 | $24M | +19% | 2.4M | 10.00 |
|
| Neurogene (NGNE) | 0.3 | $23M | 456k | 50.90 |
|
|
| Verve Therapeutics (VERV) | 0.3 | $23M | 1.7M | 13.28 |
|
|
| Tscan Therapeutics (TCRX) | 0.3 | $22M | 2.8M | 7.94 |
|
|
| Adaptimmune Therapeutics Sponsored Adr (ADAP) | 0.2 | $17M | 11M | 1.58 |
|
|
| Immunovant (IMVT) | 0.2 | $14M | 425k | 32.31 |
|
|
| 2seventy bio Common Stock (TSVT) | 0.2 | $13M | 2.5M | 5.35 |
|
|
| Fate Therapeutics (FATE) | 0.2 | $13M | NEW | 1.8M | 7.34 |
|
| Xencor (XNCR) | 0.2 | $12M | +122% | 545k | 22.13 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $12M | 4.0M | 2.87 |
|
|
| DBV Technologies Sponsored Adr (DBVT) | 0.1 | $11M | 15M | 0.75 |
|
|
| Celldex Therapeutics (CLDX) | 0.1 | $10M | 248k | 41.97 |
|
|
| Relay Therapeutics (RLAY) | 0.1 | $9.6M | 1.2M | 8.30 |
|
|
| Insmed Incorporated Com Par $.01 (INSM) | 0.1 | $9.3M | 343k | 27.13 |
|
|
| Opthea Sponsored Ads (OPT) | 0.1 | $9.0M | -15% | 2.2M | 4.11 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $8.7M | NEW | 634k | 13.75 |
|
| Athira Pharma (ATHA) | 0.1 | $8.6M | 3.2M | 2.74 |
|
|
| Dyne Therapeutics (DYN) | 0.1 | $8.1M | NEW | 285k | 28.39 |
|
| Praxis Precision Medicines I (PRAX) | 0.1 | $8.0M | NEW | 132k | 61.02 |
|
| Sage Therapeutics (SAGE) | 0.1 | $7.6M | NEW | 407k | 18.74 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $7.5M | -5% | 1.4M | 5.42 |
|
| Prime Medicine (PRME) | 0.1 | $7.2M | 1.0M | 7.00 |
|
|
| Design Therapeutics (DSGN) | 0.1 | $6.7M | +10% | 1.7M | 4.03 |
|
| Tango Therapeutics (TNGX) | 0.1 | $6.0M | 750k | 7.94 |
|
|
| Hookipa Pharma Inc equity (HOOK) | 0.1 | $5.8M | 8.1M | 0.71 |
|
|
| Mersana Therapeutics (MRSN) | 0.1 | $4.9M | 1.1M | 4.48 |
|
|
| Mirum Pharmaceuticals (MIRM) | 0.1 | $4.8M | 191k | 25.12 |
|
|
| Talis Biomedical Corporation (TLIS) | 0.1 | $4.4M | 508k | 8.75 |
|
|
| Vaxcyte (PCVX) | 0.0 | $3.3M | 49k | 68.31 |
|
|
| Century Therapeutics (IPSC) | 0.0 | $3.3M | 798k | 4.18 |
|
|
| Alpine Immune Sciences (ALPN) | 0.0 | $3.2M | NEW | 82k | 39.64 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.0 | $3.2M | NEW | 100k | 31.86 |
|
| Leap Therapeutics (LPTX) | 0.0 | $3.1M | 1.2M | 2.66 |
|
|
| Compass Therapeutics (CMPX) | 0.0 | $3.1M | 1.6M | 1.98 |
|
|
| NewAmsterdam Pharma Company Ordinary Shares (NAMS) | 0.0 | $2.3M | NEW | 97k | 23.65 |
|
| vTv Therapeutics Cl A (VTVT) | 0.0 | $2.3M | NEW | 97k | 23.53 |
|
| Kala Pharmaceuticals (KALA) | 0.0 | $2.1M | 267k | 7.97 |
|
|
| Aligos Therapeutics (ALGS) | 0.0 | $2.0M | 2.1M | 0.98 |
|
|
| Enliven Therapeutics (ELVN) | 0.0 | $2.0M | NEW | 115k | 17.59 |
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.0 | $1.5M | -42% | 1.2M | 1.25 |
|
| Generation Bio (GBIO) | 0.0 | $1.5M | NEW | 371k | 4.07 |
|
| Mural Oncology Ord Shs (MURA) | 0.0 | $1.1M | NEW | 223k | 4.89 |
|
| Pfizer (PFE) | 0.0 | $971k | 35k | 27.75 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.0 | $801k | 200k | 4.01 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $547k | 322k | 1.70 |
|
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.0 | $378k | NEW | 53k | 7.15 |
|
| Foghorn Therapeutics (FHTX) | 0.0 | $302k | 45k | 6.71 |
|
|
| Cabaletta Bio (CABA) | 0.0 | $227k | 13k | 17.06 |
|
|
| IsoRay (CATX) | 0.0 | $178k | -98% | 150k | 1.19 |
|
| Tyra Biosciences (TYRA) | 0.0 | $174k | 11k | 16.40 |
|
|
| Surrozen W Exp 8/11/2026 (SRZNW) | 0.0 | $25k | 833k | 0.03 |
|
Past Filings by Baker Bros. Advisors
SEC 13F filings are viewable for Baker Bros. Advisors going back to 2010
- Baker Bros. Advisors 2024 Q1 filed May 15, 2024
- Baker Bros. Advisors 2023 Q4 filed Feb. 14, 2024
- Baker Bros. Advisors 2023 Q3 filed Nov. 14, 2023
- Baker Bros. Advisors 2023 Q2 filed Aug. 14, 2023
- Baker Bros. Advisors 2023 Q1 filed May 15, 2023
- Baker Bros. Advisors 2022 Q4 filed Feb. 14, 2023
- Baker Bros. Advisors 2022 Q3 filed Nov. 14, 2022
- Baker Bros. Advisors 2022 Q2 filed Aug. 15, 2022
- Baker Bros. Advisors 2022 Q1 filed May 16, 2022
- Baker Bros. Advisors 2021 Q4 filed Feb. 14, 2022
- Baker Bros. Advisors 2021 Q3 filed Nov. 15, 2021
- Baker Bros. Advisors 2021 Q2 filed Aug. 16, 2021
- Baker Bros. Advisors 2021 Q1 filed May 17, 2021
- Baker Bros. Advisors 2020 Q4 filed Feb. 16, 2021
- Baker Bros. Advisors 2020 Q3 filed Nov. 16, 2020
- Baker Bros. Advisors 2020 Q2 filed Aug. 14, 2020